| Entry |
|
| Name |
Acute myeloid leukemia
|
| Description |
Acute myeloid leukemia (AML) is a disease that is characterized by uncontrolled proliferation of clonal neoplastic cells and accumulation in the bone marrow of blasts with an impaired differentiation program. AML accounts for approximately 80% of all adult leukemias and remains the most common cause of leukemia death. Two major types of genetic events have been described that are crucial for leukemic transformation. A proposed necessary first event is disordered cell growth and upregulation of cell survival genes. The most common of these activating events were observed in the RTK Flt3, in N-Ras and K-Ras, in Kit, and sporadically in other RTKs. Alterations in myeloid transcription factors governing hematopoietic differentiation provide second necessary event for leukemogenesis. Transcription factor fusion proteins such as AML-ETO, PML-RARalpha or PLZF-RARalpha block myeloid cell differentiation by repressing target genes. In other cases, the transcription factors themselves are mutated.
|
| Class |
Human Diseases; Cancers
 |
| Pathway map |

  |
| Disease |
| Acute myeloid leukemia (AML) |
|
| Reference |
|
| Authors |
Steffen B, Muller-Tidow C, Schwable J, Berdel WE, Serve H. |
| Title |
The molecular pathogenesis of acute myeloid leukemia. |
| Journal |
Crit Rev Oncol Hematol 56:195-221 (2005) |
| Reference |
|
| Authors |
Tenen DG. |
| Title |
Disruption of differentiation in human cancer: AML shows the way. |
| Journal |
Nat Rev Cancer 3:89-101 (2003) |
| Reference |
|
| Authors |
Choudhary C, Muller-Tidow C, Berdel WE, Serve H. |
| Title |
Signal transduction of oncogenic Flt3. |
| Journal |
Int J Hematol 82:93-9 (2005) |
| Reference |
|
| Authors |
Stirewalt DL, Radich JP. |
| Title |
The role of FLT3 in haematopoietic malignancies. |
| Journal |
Nat Rev Cancer 3:650-65 (2003) |
| Reference |
|
| Authors |
Martelli AM, Nyakern M, Tabellini G, Bortul R, Tazzari PL, Evangelisti C, Cocco L. |
| Title |
Phosphoinositide 3-kinase/Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia. |
| Journal |
Leukemia 20:911-28 (2006) |
| Reference |
|
| Authors |
Lennartsson J, Jelacic T, Linnekin D, Shivakrupa R. |
| Title |
Normal and oncogenic forms of the receptor tyrosine kinase kit. |
| Journal |
Stem Cells 23:16-43 (2005) |
| Reference |
|
| Authors |
Lorsbach RB, Downing JR. |
| Title |
The role of the AML1 transcription factor in leukemogenesis. |
| Journal |
Int J Hematol 74:258-65 (2001) |
| Reference |
|
| Authors |
Mizuki M, Schwable J, Steur C, Choudhary C, Agrawal S, Sargin B, Steffen B, Matsumura I, Kanakura Y, Bohmer FD, Muller-Tidow C, Berdel WE, Serve H. |
| Title |
Suppression of myeloid transcription factors and induction of STAT response genes by AML-specific Flt3 mutations. |
| Journal |
Blood 101:3164-73 (2003) |
| Reference |
|
| Authors |
Mikesch JH, Steffen B, Berdel WE, Serve H, Muller-Tidow C. |
| Title |
The emerging role of Wnt signaling in the pathogenesis of acute myeloid leukemia. |
| Journal |
Leukemia : (2007) |
| Reference |
|
| Authors |
Mueller BU, Pabst T, Fos J, Petkovic V, Fey MF, Asou N, Buergi U, Tenen DG. |
| Title |
ATRA resolves the differentiation block in t(15;17) acute myeloid leukemia by restoring PU.1 expression. |
| Journal |
Blood 107:3330-8 (2006) |
| KO pathway |
|